Merus N.V., an oncology company, has announced the publication of research detailing the mechanism of action of their bispecific antibody, petosemtamab. The antibody targets Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich G (LGR5), with findings published in the scientific journal "Cancers." Petosemtamab has shown significant clinical activity in treating recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC), with ongoing Phase 3 trials for both first-line and second/third-line treatments. Additionally, a Phase 2 trial is underway to evaluate petosemtamab in combination with standard chemotherapy for metastatic colon cancer (mCRC). The antibody works through three mechanisms: blocking EGFR ligands, causing EGFR receptor degradation in LGR5+ cells, and activating the immune system via antibody-dependent cellular phagocytosis and cytotoxicity. Initial clinical data for its application in mCRC is expected in the second half of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.